用于生物制品生产的连续细胞系的可接受性。 - Suppr

Suppr

超能文献

Acceptability of continuous cell lines for the production of biologicals.

作者信息

Löwer J

机构信息

Paul Ehrlich Institut, D-63225, Langen, Germany.

出版信息

Cytotechnology. 1995 Jan;18(1-2):15-20. doi: 10.1007/BF00744315.

DOI:10.1007/BF00744315

PMID:22358632

Abstract

摘要

相似文献

Acceptability of continuous cell lines for the production of biologicals.用于生物制品生产的连续细胞系的可接受性。

Cytotechnology. 1995 Jan;18(1-2):15-20. doi: 10.1007/BF00744315.

Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group on Biologicals.

World Health Organ Tech Rep Ser. 1987;747:1-29.

Validation of cell substrates used for human biologicals: An overview of international regulatory documents.

Toxicol In Vitro. 1990;4(4-5):720-1. doi: 10.1016/0887-2333(90)90151-i.

Cells, science and health.

Dev Biol Stand. 1989;70:3-10.

Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.生物制品生产用细胞基质的评估：世界卫生组织建议的修订。世界卫生组织生物制品生产用细胞基质研究小组报告，2009年4月22 - 23日，美国贝塞斯达

Biologicals. 2010 Jan;38(1):162-9. doi: 10.1016/j.biologicals.2009.08.019. Epub 2009 Oct 8.

WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007.世界卫生组织生物制品生产用细胞基质研究小组，瑞士日内瓦，2007年6月11 - 12日。

Biologicals. 2008 May;36(3):203-11. doi: 10.1016/j.biologicals.2007.11.005. Epub 2008 Jan 22.

Access to biologicals in Crohn's disease in ten European countries.十个欧洲国家克罗恩病生物制剂的可及性。

World J Gastroenterol. 2017 Sep 14;23(34):6294-6305. doi: 10.3748/wjg.v23.i34.6294.

Status of WHO concerning continuous cell lines as substrates for the production of biologicals.

Dev Biol Stand. 1989;70:215-9.

Safety biomarkers for development of vaccines and biologics: Report from the safety biomarkers symposium held on November 28-29, 2017, Marcy l'Etoile, France.疫苗和生物制品研发的安全性生物标志物：2017年11月28 - 29日于法国马尔西莱图瓦勒举行的安全性生物标志物研讨会报告

Vaccine. 2020 Dec 3;38(51):8055-8063. doi: 10.1016/j.vaccine.2020.10.015. Epub 2020 Nov 10.

Clinical use of biologicals produced in continuous cell lines.

Dev Biol Stand. 1989;70:211-4.

本文引用的文献

Viral validation strategy for recombinant products derived from established animal cell lines.病毒验证策略用于源自已建立的动物细胞系的重组产品。

Cytotechnology. 1995 Jan;18(1-2):21-5. doi: 10.1007/BF00744316.

The acceptability of continuous cell lines: A personal & historical perspective.连续细胞系的可接受性：个人与历史视角。

Cytotechnology. 1995 Jan;18(1-2):9-13. doi: 10.1007/BF00744314.

Theoretical considerations on viral inactivation or elimination.关于病毒灭活或清除的理论思考。

Dev Biol Stand. 1993;81:109-16.

Cellular oncogenes and multistep carcinogenesis.细胞癌基因与多步骤致癌作用

Science. 1983 Nov 18;222(4625):771-8. doi: 10.1126/science.6356358.

Tumorigenic activity of polyoma virus and SV40 DNAs in newborn rodents.多瘤病毒和猿猴空泡病毒40 DNA在新生啮齿动物中的致瘤活性。

Virology. 1984 May;135(1):53-64. doi: 10.1016/0042-6822(84)90116-8.

Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group on Biologicals.

World Health Organ Tech Rep Ser. 1987;747:1-29.

EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.欧洲经济共同体监管文件。指导说明。病毒去除和灭活程序的验证。专利药品委员会：生物技术/药学特设工作组和药品安全工作组。

Biologicals. 1991 Jul;19(3):247-51.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验